Gsa Capital Partners LLP Adverum Biotechnologies, Inc. Transaction History

Gsa Capital Partners LLP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.68 - $1.59 $514,765 - $1.2 Million	-757,008 Reduced 86.05%	122,676 $195,000
Q1 2023 May 12, 2023	BUY	$0.62 - $0.85 $30,290 - $41,526	48,855 Added 5.88%	879,684 $633,000
Q4 2022 Feb 13, 2023	BUY	$0.54 - $10.3 $405,946 - $7.74 Million	751,753 Added 950.67%	830,829 $481,000
Q3 2022 Nov 14, 2022	BUY	$0.96 - $9.68 $75,912 - $765,455	79,076 New	79,076 $75,000
Q2 2022 Aug 09, 2022	SELL	$0.81 - $1.34 $320,423 - $530,083	-395,585 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$1.23 - $1.95 $155,839 - $247,063	-126,699 Reduced 24.26%	395,585 $518,000
Q4 2021 Feb 14, 2022	BUY	$1.74 - $2.4 $908,774 - $1.25 Million	522,284 New	522,284 $919,000
Q4 2020 Feb 03, 2021	SELL	$9.84 - $14.26 $114,744 - $166,285	-11,661 Closed	0 $0
Q3 2020 Nov 06, 2020	BUY	$10.3 - $21.64 $120,108 - $252,344	11,661 New	11,661 $120,000
Q1 2020 May 12, 2020	SELL	$7.98 - $16.32 $129,898 - $265,656	-16,278 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$5.12 - $12.22 $83,343 - $198,917	16,278 New	16,278 $188,000
Q4 2018 Feb 12, 2019	SELL	$2.87 - $5.92 $42,476 - $87,616	-14,800 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$4.5 - $7.6 $66,600 - $112,480	14,800 New	14,800 $90,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.